Sélectionner la langue
Complement C3
Complement C3 Informations sur la molécule
| Nom anglais | Complement C3 | Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 13 | Alias de la cible | Complement C3，Complement Component C3a，Epididymis Secretory Sperm Binding Protein Li 62p，C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1，C3bc，C3adesArg，C3，Complement Component C3b，Complement Component 3，C3a Anaphylatoxin，Prepro-C3，CPAMD1，Acylation-Stimulating Protein Cleavage Product，HEL-S-62p，AHUS5，ARMD9，ASP，C3a，C3b |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Complement C3 |
| Alias de la cible | Complement C3，Complement Component C3a，Epididymis Secretory Sperm Binding Protein Li 62p，C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1，C3bc，C3adesArg，C3，Complement Component C3b，Complement Component 3，C3a Anaphylatoxin，Prepro-C3，CPAMD1，Acylation-Stimulating Protein Cleavage Product，HEL-S-62p，AHUS5，ARMD9，ASP，C3a，C3b |
| Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 13 |
| Phase de R&D la plus avancée | Approved |
Complement C3 Liste de produits
- Attribut
Protein (5)Kits (1)
- Bibliothèque de produits
En ligne (6)
- Espèces
Human (4)Mouse (1)Cynomolgus (1)
- Étiquette
His Tag (3)His Tag & Avi Tag (1)Fc Tag (1)- (1)
- Marqueur
Unconjugated (4)Biotin-labeled (1)- (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
HOT CO3-H52H3 |  Human | HEK293 | Human Complement C3 Protein, His Tag, low endotoxin (MALS verified) |  |  |  |  Ajouter au panier |
HOT CO3-H82E8 | Human | HEK293 | Biotinylated Human Complement C3 Protein, His,Avitag™ (MALS verified) |  | | | Ajouter au panier |
HOT CO3-M52H4 |  Mouse | HEK293 | Mouse Complement C3 Protein, His Tag (MALS verified) |  | | Ajouter au panier | |
| Human | - | Human Complement C3 ELISA Kit | Ajouter au panier | ||||
| Human | HEK293 | Human Complement component 3 Protein, Fc Tag (MALS verified) |  | | | Ajouter au panier | |
 Cynomolgus | HEK293 | Cynomolgus Complement C3 Protein, His Tag (MALS verified) |  | | | Ajouter au panier |
Quantité totale6
- 1
Complement C3Contexte de la molécule
C3 is the major complement component serum. It is mainly synthesized by macrophages and liver. C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. It is cleaved into two fragments, C3a and C3b. C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
Complement C3Alias de la molécule
Complement C3,CPAMD1
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Efdamrofusp alfa | IBI-302 | Phase 3 Clinical | AP Biosciences Inc | Diabetic macular oedema; Macular Degeneration; Plaque psoriasis; Wet Macular Degeneration | Details |
| NGM-621 | NGM-621 | Phase 2 Clinical | NGM Biopharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19); Geographic Atrophy | Details |
| RG-002-C-0106 | RG-002-C-0106; RG002C0106 | Phase 2 Clinical | Beijing Xuanjingrui Pharmaceutical Technology Co Ltd, Suzhou Xuanjing Biotechnology Co Ltd | Complement-Mediated Diseases; Glomerulonephritis, IGA; Hemolysis; Nephrotic Syndrome | Details |
| APL-3007 | APL-3007 | Phase 2 Clinical | Apellis Pharmaceuticals Inc | Geographic Atrophy | Details |
| SGB-9768 | SGB-9768 | Phase 2 Clinical | Suzhou Sanegene Bio Inc | C3 glomerulopathy; Glomerulonephritis; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Kidney Diseases | Details |
| KRIYA-825 | KRIYA-825; VV-14295 | Phase 2 Clinical | Kriya Therapeutics Inc | Geographic Atrophy | Details |
| ALXN-2030 | ALXN-2030 | Phase 2 Clinical | Alexion Pharmaceuticals Inc | Rejection of renal transplantation; Rejection of organ transplantation | Details |
| LP-005 | LP-005; RX-001 | Phase 2 Clinical | Longbio Pharma (Suzhou) Co Ltd | Amyotrophic Lateral Sclerosis; C3 glomerulopathy; Carcinoma, Non-Small-Cell Lung; Complement-Mediated Diseases; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Nephritis; Myasthenia Gravis; Periodontal Diseases; Peripheral Nervous System Diseases; Thrombotic Microangiopathies | Details |
| ARO-C3 | ARO-C3; ARO-C-3 | Phase 2 Clinical | Arrowhead Pharmaceuticals Inc | C3 glomerulopathy; Glomerulonephritis, IGA | Details |
| CG-001 | CG-001 | Phase 1 Clinical | Chengdu Konjin Co Ltd | Autoimmune Diseases; Hemoglobinuria, Paroxysmal; Myasthenia Gravis | Details |
| BI-C | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Geographic Atrophy; Retinal Diseases | Details | |
| Ebribafusp alfa | ADX-097 | Phase 1 Clinical | Q32 Bio Inc | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Glomerulonephritis, IGA; Kidney Diseases; Lupus Nephritis; Nephrosis, Lipoid | Details |
| NM3086 | NM3086; NM-3086 | Phase 1 Clinical | NovelMed Therapeutics Inc | Hemoglobinuria, Paroxysmal | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Pegcetacoplan | APL-2 | Approved | Apellis Pharmaceuticals Inc | Aspaveli, Empaveli, Syfovre | United States | Hemoglobinuria, Paroxysmal | Apellis Pharmaceuticals Inc | 2021-05-14 | Amyotrophic Lateral Sclerosis; Anemia, Hemolytic, Autoimmune; C3 glomerulopathy; Delayed Graft Function; Geographic Atrophy; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Glomerulonephritis, Membranous; Glomerulosclerosis, Focal Segmental; Hemoglobinuria, Paroxysmal; Kidney Failure, Chronic; Lupus Nephritis; Macular Degeneration; Motor Neuron Disease; Rejection of renal transplantation | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Informations sur les médicaments cliniques
Partager vers :